Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Item
http://www.wikidata.org/entity/Q37714887
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseThe CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyTyrosine kinase inhibitors: Multi-targeted or single-targeted?Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.The expanding role of nilotinib in chronic myeloid leukemia.Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.Medical decision analysis for first-line therapy of chronic myeloid leukemia.Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin.Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and
P2860

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Item
http://www.wikidata.org/entity/Q37714887
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib and nilotinib in ima ...... : a 'head-to-head comparison'.
@en
Dasatinib and nilotinib in ima ...... : a 'head-to-head comparison'.
@nl
type
label
Dasatinib and nilotinib in ima ...... : a 'head-to-head comparison'.
@en
Dasatinib and nilotinib in ima ...... : a 'head-to-head comparison'.
@nl
prefLabel
Dasatinib and nilotinib in ima ...... : a 'head-to-head comparison'.
@en
Dasatinib and nilotinib in ima ...... : a 'head-to-head comparison'.
@nl
P1433
P1476
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Dasatinib and nilotinib in ima ...... : a 'head-to-head comparison'.
@en
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921